Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

Archive ouverte

Baldacci, Simon | Mazieres, Julien | Tomasini, Pascale | Girard, Nicolas | Guisier, Florian | Audigier-Valette, Clarisse | Monnet, Isabelle | Wislez, Marie | Perol, Maurice | Do, Pascal | Dansin, Eric | Leduc, Charlotte | Leprieur, Etienne Giroux | Moro-Sibilot, Denis | Tulasne, David | Kherrouche, Zoulika | Labreuche, Julien | Cortot, Alexis

Edité par CCSD ; Impact journals -

International audience. Several mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated NSCLC have been described including the T790M mutation and METPatients with metastatic EGFR-mutated NSCLC displaying high MET overexpression or METForty two patients were included. The median overall survival (OS), and the median post EGFR TKI progression overall survival (PPOS) were 36.2 months [95%CI 27.3-66.5] and 18.5 months [95%CI 10.6-27.4] respectively. Nineteen out of 36 tumors tested for MET FISH had METMET-driven resistance to EGFR TKI defines a specific pattern of resistance characterized by low objective response rate to MET inhibitors given alone and overlapping with T790M mutations. Further studies are warranted to define adequate therapeutic strategies for MET-driven resistance to EGFR TKI.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion